Using a cardiac hypertrophy stimulant like ET-1 instead of patient specific cell lines gives us the opportunity to establish an unbiased model to focus on identifying the underlying molecular pathways that help regulate the disease mechanism. Here, EDN1 is linked to cardiac hypertrophy.